Science Immunology

Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Gating strategy of hematopoietic and myeloid precursors in the bone marrow.
  • Fig. S2. Gating strategy of myeloid subsets in the spleen and tumor site.
  • Fig. S3. Cancer-induced emergency myelopoiesis in three different mouse tumor models.
  • Fig. S4. PD-1 expression is induced on myeloid progenitors by emergency cytokines.
  • Fig. S5. Gating strategy for identification of MDSC in human blood samples.
  • Fig. S6. PD-1 expression in human MDSC.
  • Fig. S7. PD-1 ablation alters tumor-driven emergency myelopoiesis.
  • Fig. S8. PD-1 ablation induces expression of RORC and IRF8 in myeloid cells expanding in response to tumor-driven emergency myelopoiesis.
  • Fig. S9. PD-1 ablation induces expression of RORC and IRF8 in myeloid cells expanding in mice-bearing MC38 or MC17-51 tumors.
  • Fig. S10. PD-1 ablation increases the output of RORChi effector-like myeloid cells at early stages of tumor growth.
  • Fig. S11. Therapeutic targeting of PD-1 increases effector features of myeloid cells and decreases tumor growth.
  • Fig. S12. Myeloid-specific and T cell–specific PD-1 deletion.
  • Fig. S13. Myeloid-specific PD-1 ablation promotes expansion of IRF8hi and RORChi monocytes and IFN-γ–producing monocytes and macrophages in the tumor site.
  • Fig. S14. Tumor-induced emergency myelopoiesis and myeloid effector differentiation in Rag2-deficient mice treated with PD-1 antibody.
  • Fig. S15. PD-1 ablation reduces the threshold of growth factor–mediated signaling in GMP.
  • Fig. S16. Myeloid-specific PD-1 ablation induces a distinct metabolic profile characterized by elevated cholesterol.
  • Fig. S17. Metabolic pathways linking glycolysis to PPP, fatty acid, and cholesterol synthesis.
  • Fig. S18. Schematic presentation of the mevalonate pathway.
  • Fig. S19. Increase of glucose uptake and neutral lipid content in PD-1–deficient myeloid progenitors early after tumor implantation.
  • Fig. S20. Myeloid-specific PD-1 deletion alters the immunological profile of CD8+ TEM cells.
  • Fig. S21. PD-1 ablation enhances antigen presentation ex vivo by tumor-matured DC.
  • Table S1. List of significantly different metabolites.
  • Table S2. List of antibodies used for surface staining.
  • Table S3. List of antibodies used for intracellular staining.
  • Table S4. List of antibodies used for phenotype of human MDSC.
  • References (6871)

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Table S5. Raw data in Excel spreadsheet.

Files in this Data Supplement: